{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:39:14Z","timestamp":1759451954002,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Biologicals S.A","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vaccine.2019.08.065","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T08:22:25Z","timestamp":1567671745000},"page":"6171-6179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["MenACWY-CRM conjugate vaccine booster dose given 4\u20136\u202fyears after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults"],"prefix":"10.1016","volume":"37","author":[{"given":"Mary","family":"Tipton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Daly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly","family":"Senders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley L.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thembile","family":"Mzolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3996-7361","authenticated-orcid":false,"given":"Silvia","family":"Barbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-9260","authenticated-orcid":false,"given":"Michele","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavitra","family":"Keshavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.08.065_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756285609337975","article-title":"Pathophysiology and treatment of bacterial meningitis","volume":"2","author":"Hoffman","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.vaccine.2019.08.065_b0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/erv.10.3","article-title":"The epidemiology of meningococcal disease and the impact of vaccines","volume":"9","author":"Khatami","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.08.065_b0015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.08.065_b0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2019.08.065_b0025","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2019.08.065_b0030","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.065_b0035","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current epidemiology and trends in meningococcal disease-United States, 1996\u20132015","volume":"66","author":"MacNeil","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.065_b0040","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.065_b0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11910-015-0524-6","article-title":"Invasive meningococcal disease in the 21st century-an update for the clinician","volume":"15","author":"Dwilow","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2019.08.065_b0050","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.065_b0055","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.065_b0060","unstructured":"US Food and Drug administration. Package Insert \u2013 Menveo: highlights of prescribing information, 2013."},{"key":"10.1016\/j.vaccine.2019.08.065_b0065","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1016\/j.vaccine.2010.09.092","article-title":"Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2\u201310 years of age","volume":"28","author":"Halperin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.065_b0070","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/INF.0b013e31823dce5c","article-title":"Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants","volume":"31","author":"Klein","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.08.065_b0075","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":"Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine","volume":"16","author":"Reisinger","year":"2009","journal-title":"Menactra Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.08.065_b0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijid.2014.03.1390","article-title":"Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers","volume":"26","author":"Tregnaghi","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.065_b0085","unstructured":"Cohn A, MacNeil J, Clark T, Ortega-Sanchez I, Briere E, Meissner H, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Recommendat Rep 2013;62(RR-2):1\u201328."},{"key":"10.1016\/j.vaccine.2019.08.065_b0090","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"issue":"1409\u201315","key":"10.1016\/j.vaccine.2019.08.065_b0095","article-title":"Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"164","author":"Baxter","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2019.08.065_b0100","unstructured":"Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines \u2013 Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011;60:72\u20136."},{"key":"10.1016\/j.vaccine.2019.08.065_b0105","unstructured":"Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease \u2013 Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1018\u20139."},{"key":"10.1016\/j.vaccine.2019.08.065_b0110","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0b013e318279ac38","article-title":"Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents","volume":"32","author":"Jacobson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.08.065_b0115","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1016\/j.vaccine.2016.09.003","article-title":"Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine","volume":"34","author":"Robertson","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.065_b0120","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S1473-3099(18)30124-5","article-title":"Mass chemoprophylaxis for control of outbreaks of meningococcal disease","volume":"18","author":"McNamara","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.065_b0125","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1080\/21645515.2015.1136040","article-title":"Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants","volume":"12","author":"Baxter","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.08.065_b0130","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","article-title":"Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"33","author":"Baxter","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.08.065_b0135","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/INF.0000000000000866","article-title":"Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial","volume":"34","author":"Baxter","year":"2015","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:36Z","timestamp":1759401276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19311417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":27,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0264410X19311417"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MenACWY-CRM conjugate vaccine booster dose given 4\u20136\u202fyears after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}